Sprout's 'female Viagra' drug flibanserin in adcomm today; MidaTech buys DARA;

@FierceBiotech: ICYMI: Celgene narrows pioneering CAR-T collaboration with bluebird, hands over $25M sweetener.. Report | Follow @FierceBiotech

@JohnCFierce: Promo: Building #Biotech 3.0: The new rules of a changing game. Editor's corner | Follow @JohnCFierce

@DamianFierce: NantCell raised $75M (a month after NantBioScience raised $100M). News | Follow @DamianFierce

> Little Sprout Pharmaceuticals is hoping that the third try will be the charm for flibanserin, an experimental drug designed to improve women's sexual responses. An FDA adcomm meeting is being held today to review the application. Sometimes referred to as a "female Viagra," the drug has been rejected twice and heavily criticized for a marginal improvement for women enrolled in studies of the drug. The committee will vote on a recommendation later today. Story

> MidaTech is buying up DARA BioSciences ($DARA) for up to $29.7 million. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Khosla-backed Thync dodges FDA, heads to market with $299 mood-shifting, consumer wearable. Story | Follow @FierceMedDev

@EmilyWFierce: Medtronic forks over $330M to resolve IRS spat. Report | Follow @EmilyWFierce

> St. Jude Medical gets FDA OK to resume trial of Portico TAVR. More

> Calhoun Vision raises $69M for light adjustable intraocular lens FDA approval, launch. Story

> Dexcom, Insulet partner with diabetes data startup Glooko as it expands into insulin pumps, CGMs. Article

Pharma News

@FiercePharma: #ICYMI yesterday: AZ's Soriot lashes out at U.K.'s refusal to pay for first-in-class cancer drug. Article | Follow @FiercePharma

@EricPFierce: #FDA warning letter says Czech company shipped bacteria contaminated APIs to the US. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer faces uphill battle for Stiolto, thanks to payer arm-twisting. More | Follow @CarlyHFierce

> Novartis asks court to take the brakes off Neupogen biosim. More

> Shire's bid to block Lialda copies hits another snag. News

Vaccines News

> Researchers try doctor 'interventions' to boost childhood vax rates. Article

> Merck, Amgen to test Keytruda/T-Vec combo in head and neck cancer. More

> Takeda to consolidate U.S. vaccines ops in Cambridge. Story

> VaxInnate brings seasonal flu vaccine into Phase II. Report

> Celldex's brain cancer vaccine Rintega posts survival edge in PhII. Article

CRO News

> CRO Veristat eyes a roomier HQ after years of growth. Item

> WuXi lands a role in the U.K.'s plot to sequence 100,000 genomes. News

> Quintiles cuts the ribbon on a new Chinese R&D hub. Report

> Recipharm signs on to develop Follicum's hair-growth drug. Article

> AMRI partners up in drug discovery amid a corporate turnaround. Story

Pharma Manufacturing News

> U.S. company gets cGMP certification for Slovenia plant to produce bacteriophages. Article

> DARA to get nanoparticle plant in deal to buy Midatech Pharma. News

> Indian telemarketer of foreign-made drugs goes to federal prison. More

> Indian industry acknowledges some compliance shortcomings, survey finds. Story

> Pozen has a new CEO to deal with the FDA's API concerns. Article

Pharma Asia News

> Takeda consolidates in U.S. amid sharp global vaccine competition. More

> India's NPPA says it really means this deadline on registration. Story

> Celgene's Abraxane denied by India patent office, local generics seen ahead. Article

> Japan aims for high-end drug-device innovation and generics, but will it work? News

> China says papers on MERS candidate to be published soon. Item

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.